Fintel reports that on October 30, 2025, Cantor Fitzgerald maintained coverage of Vanda Pharmaceuticals (NasdaqGM:VNDA) with a Overweight recommendation.
Analyst Price Forecast Suggests 198.73% Upside
As of October 30, 2025, the average one-year price target for Vanda Pharmaceuticals is $12.92/share. The forecasts range from a low of $5.05 to a high of $21.00. The average price target represents an increase of 198.73% from its latest reported closing price of $4.32 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Vanda Pharmaceuticals is 282MM, an increase of 32.74%. The projected annual non-GAAP EPS is 1.48.
What is the Fund Sentiment?
There are 322 funds or institutions reporting positions in Vanda Pharmaceuticals. This is an decrease of 17 owner(s) or 5.01% in the last quarter. Average portfolio weight of all funds dedicated to VNDA is 0.04%, an increase of 8.51%. Total shares owned by institutions increased in the last three months by 0.52% to 51,124K shares. 
The put/call ratio of VNDA is 0.18, indicating a bullish outlook.
What are Other Shareholders Doing?
Renaissance Technologies holds 3,447K shares representing 5.83% ownership of the company. In its prior filing, the firm reported owning 3,566K shares , representing a decrease of 3.45%. The firm decreased its portfolio allocation in VNDA by 12.63% over the last quarter.
Millennium Management holds 3,120K shares representing 5.28% ownership of the company. In its prior filing, the firm reported owning 2,140K shares , representing an increase of 31.43%. The firm increased its portfolio allocation in VNDA by 36.07% over the last quarter.
Tang Capital Management holds 2,353K shares representing 3.98% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,743K shares representing 2.95% ownership of the company. No change in the last quarter.
Acadian Asset Management holds 1,732K shares representing 2.93% ownership of the company. In its prior filing, the firm reported owning 1,887K shares , representing a decrease of 8.96%. The firm decreased its portfolio allocation in VNDA by 31.05% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
